Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for moderate to severe irritable bowel syndrome
IRCT20090117001556N105Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of vortioxetine in irritable bowel syndrome (IBS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of symptoms. Started Jan 2018; status: completed.
02
Drugs
vortioxetine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20090117001556N105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N105.